30th August，2019 — Can-Fite BioPharma Ltd. issued an announcement, which is summarized as follows:
– Preparatory work for an End of Phase II meeting with FDA to initiate Phase III study in liver cancer is ongoing
– Patient enrollment continues in two Phase III studies for Piclidenoson in the treatment of rheumatoid arthritis and psoriasis
– Top-line data from Phase II NASH study with Namodenoson expected Q4 2019
Preparing for End-of-Phase II Study and Initiation of Planned Phase III for Namodenoson in Liver Cancer – The Company is now preparing for an end-of-Phase II meeting with the FDA in which Can-Fite will review the data from its recently completed Phase II study in patients with hepatocellular cancer (HCC), the most common form of liver cancer, and present the design of its planned Phase III trial, which it expects to initiate following agreement with the FDA.
Phase II Liver Cancer Data Presented at ASCO – Data from Can-Fite’s recently completed Phase II trial in patients with HCC was presented at the late-breaking abstract session of the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO), the world’s largest clinical cancer research meeting. The most impressive finding was that in the largest subgroup of patients, those with Child Pugh B7, 44% of the patients treated with Namodenoson were alive at one-year post treatment compared to 18% in the placebo group, despite the trial not achieving its primary endpoint.
The original website link: